| Placebo | Selexipag | |
| Subjects n | 10 | 33 |
| Time from diagnosis yrs | 4.0±3.1 | 5.5±6.1 |
| PVR dyn·s·cm−5 | 867.2±379.3 | 928.6±436.6 |
| 6-min walk distance m | 350.3±123.5 | 396.2±71.4 |
| WHO FC | ||
| I | ||
| II | 2 (20.0) | 15 (45.5) |
| III | 8 (80.0) | 18 (54.5) |
| IV | ||
| Borg dyspnoea score | 4.1±2.6 | 3.3±2.1+ |
| NT-proBNP pg·mL−1# | 2400.9±1269.8¶ | 1601.4±2443.0§ |
| Background PAH therapy | ||
| ERA monotherapy | 4 (40.0) | 12 (36.4) |
| Sildenafil monotherapy | 3 (30.0) | 9 (27.2) |
| ERA plus sildenafil | 3 (30.0) | 12 (36.4) |
Data are presented as mean±sd or n (%), unless otherwise stated. PVR: pulmonary vascular resistance; WHO FC: World Health Organization functional class; NT-proBNP: N-terminal pro-brain natriuretic peptide; ERA: endothelin receptor antagonist. #: Upper reference values are 100 pg·mL−1 and 172 pg·mL−1 for males aged 45–59 and ≥60 yrs, respectively, and 164 pg·mL−1 and 225 pg·mL−1 for females aged 45–59 and ≥60 yrs, respectively [18]; ¶: n=8; +: n=32; §: n=27.